RT Conference Proceedings
T1 LESS THAN 5% OF REAL-LIFE PATIENTS WHO SWITCH FROM IV TO SC ABATACEPT IN REAL-WORLD CLINICAL PRACTICE SUBSEQUENTLY SWITCH BACK TO THE IV FORMULATION
A1 Alten, R.
A1 Lorenz, H-M.
A1 Mariette, X.
A1 Nuesslein, H.
A1 Galeazzi, M.
A1 Navarro, F.
A1 Chartier, M.
A1 Heitzmann, J.
A1 Rauch, C.
A1 Le Bars, M.
K1 Subcutaneous formulation
PB Bmj publishing group
SN 0003-4967
YR 2017
FD 2017-06-01
LK https://hdl.handle.net/10668/27639
UL https://hdl.handle.net/10668/27639
LA en
DS RISalud
RD Apr 12, 2025